14.3.2017 15:24 | Business Wire
First Fibroblast Injection Performed in SpinalCyte’s Landmark Trial for Spinal Disc Regeneration
SpinalCyte, LLC , a Texas-based tissue engineering technology company focused on the regrowth of the spinal disc nucleus using human dermal fibroblasts, announced the first injection of fibroblasts for the regeneration of the spinal disc. CybroCell is the first dermal fibroblast product for treatment of degenerative disc disease. The procedure was completed in less than 15 minutes using a local anesthetic. The patient experienced no complications and was discharged within an hour.
“This historic moment marks the first time a human patient has received dermal fibroblasts for treatment of degenerative disc disease,” said SpinalCyte Chief Executive Officer Pete O’Heeron. “Our preclinical trials resulted in significant regrowth of the spinal disc nucleus, increases in disc height, and gene expression such as proteoglycan with only one injection of fibroblasts. Using CybroCell, our off-the-shelf allogeneic dermal fibroblasts, we aim to build on our earlier clinical successes for treatment of degenerative disc disease.”
The clinical trial will enroll 18 patients between the ages of 18 and 85. Each patient will be administered CybroCell alone, in combination with platelet-rich plasma (PRP), or saline only. SpinalCyte aims to show that using its off-the-shelf, allogeneic “prepackaged” cell therapy product, CybroCell will lead to a reduction in pain, improved function, and regeneration of damaged discs.
“We believe this technology has the potential to emerge as the “first choice” cell-therapy option for spinal disc repair,” said Carlos Manuel Ruiz Macias, M.D., Principal Investigator of the SpinalCyte clinical trials. “CybroCell can offer a life-changing opportunity for millions of people around the world who deal with back pain and problems due to injury, age, or other factors.”
To learn more about SpinalCyte, LLC, please visit www.spinalcyte.com .
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. Currently, SpinalCyte holds 21 U.S. and international issued patents, and has filed for an additional 43 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
DELTICOM-AG/MOTO-TYRES18.8.2017 11:24 | pressemeddelelse
Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!
NC-LENOVO-NCTA18.8.2017 02:06 | pressemeddelelse
Lenovo Continues to Gain Momentum in First Quarter FY 2017/18
SPIRENT-COMMUNICATIONS17.8.2017 17:59 | pressemeddelelse
Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye
BIZWIRETV17.8.2017 14:10 | pressemeddelelse
Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate
PA-PSIOXUS-THERAPEUTICS17.8.2017 09:02 | pressemeddelelse
PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence
SMARSH-INC/COGNIA17.8.2017 09:01 | pressemeddelelse
Smarsh Adds Voice Archiving Offering with Acquisition of London-Based Cognia
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum